Ontology highlight
ABSTRACT: Importance
The BEACON trial showed that combination therapy with encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) was associated with prolonged overall survival compared with standard chemotherapy in patients with metastatic BRAF variant colorectal cancer. However, the cost-effectiveness of using these agents in this clinical setting is unknown.Objective
To create a cost-effectiveness model to compare doublet therapy (encorafenib plus cetuximab) with standard chemotherapy (cetuximab plus irinotecan or cetuximab plus folinic acid, fluorouracil, and irinotecan) in treating patients with metastatic BRAF variant colorectal cancer.Design, setting, and participants
This economic evaluation constructed a Markov model to compare the lifetime cost and utility of d
SUBMITTER: Patel KK
PROVIDER: S-EPMC7804917 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature